Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > START chosen to test drug compound that suppresses cancer-causing genes

March 13th, 2008

START chosen to test drug compound that suppresses cancer-causing genes

Abstract:
South Texas Accelerated Research Therapeutics (START) has been selected as one of two clinics that will conduct Phase I trials for an anti-cancer compound developed by Calando Pharmaceuticals.

Calando also submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration to initiate the clinical trial for the drug, CALAA-01.

The drug is a targeted nanoparticle designed to activate the body's natural mechanism to "silence" the "inappropriate activity" of specific genes causing cancer. The trial will evaluate whether CALAA-01 is safe and tolerable by humans. Anthony Tolcher, M.D., director of clinical research at START, will be leading the study in San Antonio.

START is a partnership that directs clinical trials of novel anticancer agents and is headquartered at San Antonio's South Texas Medical Center. The group is constructing a new 120,000-square-foot office headquarters building, scheduled to open in July 2008.

Source:
bizjournals.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016

Nanomedicine

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Nanoscale Trojan horses treat inflammation May 24th, 2016

Announcements

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Doubling down on Schrödinger's cat May 27th, 2016

Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic